abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
91919: OncoVantage™ Print View
Tumor Tissue Type:      
Block ID:      
Diagnosis:      
Source:      
Stage at Presentation:      
Grade:      
Overall Interpretation      
Gene Name #1      
Mutation #1      
Alteration Type #1      
Mutation Frequency #1     % Frequency 
Tumor Type Drugs #1      
Non-Tumor Type Drugs #1      
Clinical Trials #1      
Gene Name #2      
Mutation #2      
Alteration Type #2      
Mutation Frequency #2     % Frequency 
Tumor Type Drugs #2      
Non-Tumor Type Drugs #2      
Clinical Trials #2      
Gene Name #3      
Mutation #3      
Alteration Type #3      
Mutation Frequency #3     % Frequency 
Tumor Type Drugs #3      
Non-Tumor Type Drugs #3      
Clinical Trials #3      
Gene Name #4      
Mutation #4      
Alteration Type #4      
Mutation Frequency #4     % Frequency 
Tumor Type Drugs #4      
Non-Tumor Type Drugs #4      
Clinical Trials #4      
Gene Name #5      
Mutation #5      
Alteration Type #5      
Mutation Frequency #5     % Frequency 
Tumor Type Drugs #5      
Non-Tumor Type Drugs #5      
Clinical Trials #5      
Gene Name #6      
Mutation #6      
Alteration Type #6      
Mutation Frequency #6     % Frequency 
Tumor Type Drugs #6      
Non-Tumor Type Drugs #6      
Clinical Trials #6      
Gene Name #7      
Mutation #7      
Alteration Type #7      
Mutation Frequency #7     % Frequency 
Tumor Type Drugs #7      
Non-Tumor Type Drugs #7      
Clinical Trials #7      
Gene Name #8      
Mutation #8      
Alteration Type #8      
Mutation Frequency #8     % Frequency 
Tumor Type Drugs #8      
Non-Tumor Type Drugs #8      
Clinical Trials #8      
Interacting Mutations      
Additional Mutations      
Gene Function #1      
Mutation Effect on Gene #1      
FDA Tumor Drugs #1      
FDA Non-Tumor Drugs #1      
Clinical Trials #1      
Companion Diagnostics #1      
Gene Function #2      
Mutation Effect on Gene #2      
FDA Tumor Drugs #2      
FDA Non-Tumor Drugs #2      
Clinical Trials #2      
Companion Diagnostics #2      
Gene Function #3      
Mutation Effect on Gene #3      
FDA Tumor Drugs #3      
FDA Non-Tumor Drugs #3      
Clinical Trials #3      
Companion Diagnostics #3      
Gene Function #4      
Mutation Effect on Gene #4      
FDA Tumor Drugs #4      
FDA Non-Tumor Drugs #4      
Clinical Trials #4      
Companion Diagnostics #4      
Gene Function #5      
Mutation Effect on Gene #5      
FDA Tumor Drugs #5      
FDA Non-Tumor Drugs #5      
Clinical Trials #5      
Companion Diagnostics #5      
Gene Function #6      
Mutation Effect on Gene #6      
FDA Tumor Drugs #6      
FDA Non-Tumor Drugs #6      
Clinical Trials #6      
Companion Diagnostics #6      
Gene Function #7      
Mutation Effect on Gene #7      
FDA Tumor Drugs #7      
FDA Non-Tumor Drugs #7      
Clinical Trials #7      
Companion Diagnostics #7      
Gene Function #8      
Mutation Effect on Gene #8      
FDA Tumor Drugs #8      
FDA Non-Tumor Drugs #8      
Clinical Trials #8      
Companion Diagnostics #8      
Gene Regions Passing QC      
Always Statement      
Publications      

PRIMARY
1 Tissue Paraffin Block   Refrigerated - 12 Month(s)/Room Temperature - 12 Month(s)  
ALTERNATE
  DNA, extracted   Refrigerated - 3 Month(s)/Room Temperature - 14 Day(s)/Frozen - 12 Month(s)  
  Cell Pellet   Room Temperature - 30 Day(s)/Refrigerated - 30 Day(s)  

This multiplex test will allow physicians to choose the most appropriate therapy for their patients based on the alterations found in the individual's tumor sample DNA. Guidelines exist for using results from many of these genes for selection of FDA approved therapies. By testing for other genes the physician can become aware of alternative treatments available to the patient based on presence of mutations in other genes the physicians might not have considered. Additional genes indicate prognosis of those patients with mutations, thus allowing physicians and patients to choose more or less aggresive therapies. Finally, mutations found in additional genes will qualify patients for ongoing or planned clinical trials. IBM Watson Genomics from Quest Diagnostics genes tested: AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, ESR1, FBXW7, FGFR2, FGFR3, FGFR4, FOXL2, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MET, NOTCH1, NRAS, PDGFRA, PIK3CA, PIK3R1, PTCH1, PTEN, RET, SMO, STK11, TP53, VHL.

For submission of paraffin block, tumor tissue type and block ID
are required on the requisition form.
A pathology report must be submitted.
Setup Schedule
Friday

Reported (Analytical Time)
14 days

CPT Code
81445

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
Reject Criteria: Baked slides; received frozen METHODOLOGY: Next Generation Sequencing/Ion Torrent Personal Genome Machine Transport Temperature: Room temperature






© 1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database